Over- or De-Sialylated Antibodies Service

Creative Biolabs has established the GlycoOpitimize™ platform based on our extensive experience during the development of antibody glycoengineering technology. Clients all over the world can get our efficient one-stop solution of antibody glycoengineering. Creative Biolabs’ over- or de-sialylated antibodies service can work with our clients to overcome challenges on antibody production, cell line development, biopharmaceutical process development and glycan analysis. Creative Biolabs is dedicated to providing efficient and economically feasible solutions.

High dose of intravenous immunoglobulin (IVIG) has been approved to treat many auto-immune diseases. Studies have repeatedly proven that the N-glycans at Fc Asn297 site are indispensable for this anti-inflammatory activity. It was further revealed that the α2,6-linked sialic acid on the Asn297 N-glycan conferred this property. The antennary sialic acid residues can increase the expression of the inhibitory Fcγ receptor IIb (FcγR IIb) and meanwhile reduce the binding affinity to the Fcγ receptor III. The C-type lectin receptor DC-SIGN is one of the possible receptors of α2,6-sialylated Fc. Different protocols have been used to generate over-sialylated antibodies, such as SNA lectin affinity chromatography or more effectively, in vitro enzymatic treatment with β1,4-galactosyltransferase and α2,6-sialyltransferases. In the contrary, some reports showed that de-sialylated antibodies can exhibit about 2-fold of ADCC activity relative to the normal sialylated antibodies while possess the same pharmacokinetics and antigen-binding characteristics.

Creative Biolabs has developed many frontier techniques in the field of glyco-engineering on our GlycoOpitimize™ platform. We are able to produce glyco-engineered antibodies in various bio-engineered mammalian or non-mamalian cell line systems, and using in vitro enzymic or chemo-enzymatic method. The quality of our service will be guaranteed by our antibody glycan analysis systems. Send us your project description and needs and you can get a tailored all-in-one service to meet your R&D or cGMP production needs.



  1. Anthony RM, Ravetch JV. (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. Journal of clinical immunology, 30(1), 9-14.

For research use only. Not intended for any clinical use.

Send Inquiry

© 2021 Creative BioLabs. All Rights Reserved
  • 0
  • 0